Cryo-Cell Insider Purchases: Portnoy Acquires 42,900 CCEL Shares
Rhea-AI Filing Summary
Insider purchases by Cryo-Cell International director and 10% owner David Portnoy are reported across September 8-10, 2025. The Form 4 shows multiple open-market purchases of Common Stock at prices between $4.30 and $4.49, including a 5,271-share purchase at a weighted average $4.31 on 09/08/2025 and a series of purchases on 09/09-09/10/2025. The listed transactions total 42,900 shares acquired during the reported dates, and the filing details existing indirect holdings and option positions, including several outstanding stock options covering 529,879 shares in the aggregate. The report is signed by David Portnoy.
Positive
- Insider buying: David Portnoy acquired a total of 42,900 shares across 09/08-09/10/2025 at weighted prices between $4.30 and $4.49, indicating management purchases.
- Transparent disclosure: The Form 4 lists direct and indirect holdings, custodial purchases for family accounts, and affiliated entity holdings, supporting regulatory transparency.
Negative
- Potential dilution: The filing discloses outstanding stock options covering a total of 529,879 shares, which could dilute existing shareholders if exercised.
- Concentrated insider ownership: Significant indirect holdings through related entities and partnerships concentrate control, which may raise governance concerns for some investors.
Insights
TL;DR: Significant insider purchases totaling 42,900 shares across three days signal executive buy-side activity at ~$4.30-$4.49 per share.
The Form 4 documents repeated purchases by a director/10% owner, which can be interpreted as management demonstrating confidence in the company at current market prices. Transactions are executed via IRA, as custodian for family, by spouse, corporation holdings and other indirect vehicles, showing coordinated accumulation across accounts. The filing also discloses substantial outstanding option grants (totaling 529,879 options), which may dilute equity if exercised. Overall, the activity is investor-relevant but routine for insiders increasing exposure.
TL;DR: Multiple direct and indirect purchases by a senior insider increase beneficial ownership and raise governance transparency questions around related-party holdings.
The disclosure is thorough about the nature of indirect ownership through IRAs, family custodial accounts and affiliated entities, and it clarifies roles where the reporting person may be deemed beneficial owner of shares held by PartnerCommunity, uTIPu, and a Mayim partnership. This level of aggregation is appropriate for Section 16 compliance. Stakeholders should note concentration of ownership and the large pool of executive options that remain outstanding, which are fully disclosed in Table II.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Purchase | Common Stock | 11,035 | $4.40 | $49K |
| Purchase | Common Stock | 4,817 | $4.47 | $22K |
| Purchase | Common Stock | 7,178 | $4.42 | $32K |
| Purchase | Common Stock | 7,200 | $4.48 | $32K |
| Purchase | Common Stock | 2,087 | $4.48 | $9K |
| Purchase | Common Stock | 4,815 | $4.49 | $22K |
| Purchase | Common Stock | 185 | $4.49 | $830.65 |
| Purchase | Common Stock | 156 | $4.48 | $698.88 |
| Purchase | Common Stock | 156 | $4.49 | $700.44 |
| Purchase | Common Stock | 5,271 | $4.31 | $23K |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Stock Option | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
| holding | Common Stock | -- | -- | -- |
Footnotes (1)
- The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.30 to $4.32, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.48 to $4.49, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $4.20 to $4.45, inclusive. The reporting person undertakes to provide to Cryo-Cell International, Inc. (the "Company"), any security holder of the Company or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in this footnote. Shares of Common Stock held by PartnerCommunity, Inc., as to which David I. Portnoy may be deemed beneficial owner as the Chairman of the Board and Secretary. Shares of common stock held by uTIPu, Inc. as to which David Portnoy may be deemed the beneficial owner as the Chairman of the Board and Secretary. Shares of common stock held by Mayim Limited Partnership as is David Portnoy may be deemed the beneficial owner as the managing member and owner of Mayim Management, LLC, which is the general partner of Mayim Management Limited Partnership, which is the general partner of Mayim Investment Limited Partnership. Stock options will vest immediately if the price of the Company's common stock reaches $25.00 per share during the seven-year option term. 8,750 stock options vest upon issuance, 8,749 options vest on 1/2/2024, 21,000 options vest on 1/2/2025 and 11,501 options vest on 1/2/2026. Stock options vest 1/3 upon issuance, 1/3 on December 22, 2024 and 1/3 on December 22, 2025. Stock options vest 1/3 upon issuance, 1/3 on January 21, 2026 and 1/3 on January 21, 2027.
